BackInVivo Therapeutics Holdings Overview

InVivo Therapeutics Holdings Research & Development

Research & Development expenses for NVIV.

Quarterly R&D Expenses

$703000.00
↓ 39.81% YoY

As of Sep 30, 2023

Annual R&D Expenses (TTM)

$4.08M
↓ 22.65% YoY

Trailing 12 months ending Sep 30, 2023

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin